These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 39213141)

  • 1. Patient liability, treatment adherence, and treatment persistence associated with state bans of copay accumulator adjustment programs.
    Patel A; Sheinson D; Wong WB
    J Manag Care Spec Pharm; 2024 Sep; 30(9):909-916. PubMed ID: 39213141
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of a co-pay accumulator adjustment program on specialty drug adherence.
    Sherman BW; Epstein AJ; Meissner B; Mittal M
    Am J Manag Care; 2019 Jul; 25(7):335-340. PubMed ID: 31318506
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of racial and ethnic inequities in copay card utilization and enrollment in copay adjustment programs.
    Ingham M; Sadik K; Zhao X; Song J; Fendrick AM
    J Manag Care Spec Pharm; 2023 Sep; 29(9):1084-1092. PubMed ID: 37548953
    [No Abstract]   [Full Text] [Related]  

  • 4. Impact of Patient Reimbursement Timing and Patient Out-of-Pocket Expenses on Medication Adherence in Patients Covered by Private Drug Insurance Plans.
    Després F; Forget A; Kettani FZ; Blais L
    J Manag Care Spec Pharm; 2016 May; 22(5):539-47. PubMed ID: 27123915
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A primer on copay accumulators, copay maximizers, and alternative funding programs.
    Choi D; Zuckerman AD; Gerzenshtein S; Katsivalis KV; Nichols PJ; Saknini MC; Schneider MP; Taylor P; Dusetzina SB
    J Manag Care Spec Pharm; 2024 Aug; 30(8):883-896. PubMed ID: 39088335
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Out-of-Pocket and Health Care Spending Changes for Patients Using Orally Administered Anticancer Therapy After Adoption of State Parity Laws.
    Dusetzina SB; Huskamp HA; Winn AN; Basch E; Keating NL
    JAMA Oncol; 2018 Jun; 4(6):e173598. PubMed ID: 29121177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of teriparatide adherence and persistence with clinical and economic outcomes in Medicare Part D recipients: a retrospective cohort study.
    Hazel-Fernandez L; Louder AM; Foster SA; Uribe CL; Burge RT
    BMC Musculoskelet Disord; 2013 Jan; 14():4. PubMed ID: 23281846
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increasing time costs and copayments for prescription drugs: an analysis of policy changes in a complex environment.
    Domino ME; Martin BC; Wiley-Exley E; Richards S; Henson A; Carey TS; Sleath B
    Health Serv Res; 2011 Jun; 46(3):900-19. PubMed ID: 21306363
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Higher costs and therapeutic factors associated with adherence to NCQA HEDIS antidepressant medication management measures: analysis of administrative claims.
    Robinson RL; Long SR; Chang S; Able S; Baser O; Obenchain RL; Swindle RW
    J Manag Care Pharm; 2006; 12(1):43-54. PubMed ID: 16420107
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of oral anticancer parity laws on out-of-pocket spending and adherence among commercially insured patients with chronic myeloid leukemia.
    Spargo A; Yost C; Squires P; Raju A; Schroader B; Brown JD
    J Manag Care Spec Pharm; 2021 May; 27(5):554-564. PubMed ID: 33908275
    [No Abstract]   [Full Text] [Related]  

  • 11. Impact of a Patient Support Program on Patient Adherence to Adalimumab and Direct Medical Costs in Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis, and Ankylosing Spondylitis.
    Rubin DT; Mittal M; Davis M; Johnson S; Chao J; Skup M
    J Manag Care Spec Pharm; 2017 Aug; 23(8):859-867. PubMed ID: 28737994
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluating the relationship between quality measure adherence definitions and economic outcomes in commercial health plans: a retrospective diabetes cohort study.
    Chinthammit C; Axon DR; Mollon L; Taylor AM; Pickering M; Black H; Warholak T; Campbell PJ
    J Manag Care Spec Pharm; 2021 Jan; 27(1):64-72. PubMed ID: 33377445
    [No Abstract]   [Full Text] [Related]  

  • 13. Real-World Adherence to and Persistence with Vibegron in Patients with Overactive Bladder: A Retrospective Claims Analysis.
    Chastek B; Carrera A; Landis C; Snyder D; Abedinzadeh L; Bancroft T; Nesheim J; Kennelly M; Staskin D
    Adv Ther; 2024 May; 41(5):2086-2097. PubMed ID: 38520502
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-World Health Plan Data Analysis: Key Trends in Medication Adherence and Overall Costs in Patients with HIV.
    Kangethe A; Polson M; Lord TC; Evangelatos T; Oglesby A
    J Manag Care Spec Pharm; 2019 Jan; 25(1):88-93. PubMed ID: 30589631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adherence and Persistence with DPP-4 Inhibitors Versus Pioglitazone in Type 2 Diabetes Patients with Chronic Kidney Disease: A Retrospective Claims Database Analysis.
    Gor D; Lee TA; Schumock GT; Walton SM; Gerber BS; Nutescu EA; Touchette DR
    J Manag Care Spec Pharm; 2020 Jan; 26(1):67-75. PubMed ID: 31880221
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adherence to statin therapy under drug cost sharing in patients with and without acute myocardial infarction: a population-based natural experiment.
    Schneeweiss S; Patrick AR; Maclure M; Dormuth CR; Glynn RJ
    Circulation; 2007 Apr; 115(16):2128-35. PubMed ID: 17420348
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Persistence, adherence, and all-cause healthcare costs in atazanavir- and darunavir-treated patients with human immunodeficiency virus in a real-world setting.
    Farr AM; Johnston SS; Ritchings C; Brouillette M; Rosenblatt L
    J Med Econ; 2016; 19(4):386-96. PubMed ID: 26640980
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Persistence and adherence to ocrelizumab compared with other disease-modifying therapies for multiple sclerosis in U.S. commercial claims data.
    Engmann NJ; Sheinson D; Bawa K; Ng CD; Pardo G
    J Manag Care Spec Pharm; 2021 May; 27(5):639-649. PubMed ID: 33624535
    [No Abstract]   [Full Text] [Related]  

  • 19. Impact of a transition to more restrictive drug formulary on therapy discontinuation and medication adherence.
    Shirneshan E; Kyrychenko P; Matlin OS; Avila JP; Brennan TA; Shrank WH
    J Clin Pharm Ther; 2016 Feb; 41(1):64-9. PubMed ID: 26778812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment patterns and health care costs among patients with psoriatic arthritis treated with biologic or targeted synthetic disease-modifying antirheumatic drugs.
    Murage MJ; Princic N; Park J; Malatestinic WN; Zhu B; Atiya B; Kern SA; Stenger KB; Sprabery AT; Ogdie A
    J Manag Care Spec Pharm; 2022 Feb; 28(2):206-217. PubMed ID: 35098751
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.